Related by context. All words. (Click for frequent words.) 69 APOPTONE 68 CGEN # 68 riociguat 68 GRNCM1 67 systemically administered 67 nonclinical studies 66 preclinical efficacy 66 cannabinor 66 ImmunoVEX HSV2 66 tumorigenicity 65 EndoTAG TM -1 65 ARIKACE ™ 65 ReN# 65 ENMD # 65 CA4P 65 OXi# 65 favorable pharmacokinetic profile 65 QTinno TM 64 PROCHYMAL 64 MAGE A3 ASCI 64 Panzem 64 triphendiol 64 rBChE 64 GRN# 64 hereditary deficiency 64 PSMA ADC 64 CCR9 antagonist 64 plasma kallikrein 64 mTOR inhibitors 64 antiangiogenic activity 64 fibrotic disease 64 eTag assays 64 PEG SN# 63 masitinib 63 NV1FGF 63 sd rxRNA 63 Symadex 63 ANAVEX #-# [001] 63 PD LID 63 QuadraSphere 63 PSN# [002] 63 oral prodrug 63 preclinically 63 PLX cells 63 Trofex 63 DXL# 63 Mipomersen 63 INCB# [001] 63 PRT# 63 TRIOLEX 63 chemopreventive agent 63 HCV protease inhibitors 63 ruxolitinib 63 antifibrotic 63 Tß4 63 fumagillin nanoparticles 63 Sym# 63 ProSavin 63 pharmacodynamic properties 63 Azedra 63 enzastaurin 63 CCX# 63 EDEMA3 trial 63 anti fibrotic 63 Triolex 63 metaglidasen 63 alvespimycin 63 bioresorbable stent 63 vidofludimus 63 vivo validation 63 omega interferon 63 CTAP# Capsules 63 PS# [001] 63 neuroprotective properties 63 RGB # 62 dacetuzumab 62 preclinical studies 62 tezampanel NGX# 62 CIMZIA ™ 62 urocortin 2 62 adipiplon 62 lomitapide 62 Zybrestat 62 BNC# 62 ELACYT 62 OncoVEX GM CSF 62 viral kinetics 62 ZOLINZA 62 dexanabinol 62 vitro experiments 62 TNF antagonist 62 #ME# 62 talactoferrin 62 UPLYSO 62 BrachySil TM 62 either acutely decompensated 62 preclinical 62 anticancer activity 62 iSONEP 62 OHR/AVR# 62 canagliflozin 62 Arikace 62 brivaracetam 62 MYDICAR 62 ALN TTR# 62 potent antitumor activity 62 Zalypsis 62 NLX P# 62 telomerase inhibition 62 adecatumumab 62 rtPA 62 preclinical pharmacokinetic 62 Serdaxin 62 small molecule activators 62 trodusquemine 62 QTc prolongation 62 MGd 62 forodesine 62 CIMZIA TM 62 selective modulator 62 NEUMUNE 62 immune modulatory 62 anthracycline chemotherapy 62 Apoptone 62 OncoVEX 62 ADVEXIN therapy 62 XmAb# 62 bardoxolone methyl 61 phase IIb clinical 61 cortical stimulation 61 huC# DM4 61 Phase Ib study 61 eltrombopag 61 schizophrenia CIAS 61 multicenter Phase II 61 eprotirome 61 PXD# 61 ZFP TF 61 midstage clinical trials 61 #D#C# 61 sd rxRNA compounds 61 bovine thrombin 61 Xanafide 61 ToGA 61 elacytarabine 61 TELINTRA 61 ATPace TM 61 vivo potency 61 Viramidine 61 CA9 SCAN 61 ostarine 61 antitumor effect 61 tipifarnib 61 HuMax EGFr 61 molecular determinants 61 PDE# inhibitors 61 ADAGIO study 61 HuMax CD# 61 MyVax 61 ularitide 61 antiangiogenic therapy 61 pharmacodynamic parameters 61 vivo efficacy 61 FTIs 61 tezampanel 61 E2F Decoy 61 VEGF inhibitors 61 vascular disrupting agent 61 isoform selective 61 BETAS 61 novel VDA molecule 61 K ras mutations 61 ganetespib 61 antiproliferative effects 61 midstage clinical 61 antiangiogenic agent 61 opioid analgesia 61 HuLuc# 61 Ceflatonin 61 bicifadine 61 atacicept 61 Lixivaptan 61 Vernakalant 61 Aplidin 61 anti angiogenic agents 61 secretin 61 CBLC# 61 AGHD 61 MET amplification 61 uricase 61 SAR# [004] 61 Guanilib 61 velafermin 61 fosbretabulin 61 #beta HSD1 61 CYT# potent vascular disrupting 61 pharmacodynamic profile 61 Prodarsan ® 61 R#/MEM # 61 DACH platinum 61 Valortim 61 histone deacetylase inhibitor 61 phase IIa clinical 61 thetreatment 61 EndoTAG TM 61 antitumor efficacy 61 tafamidis 61 urate lowering 61 ALGRX 61 Factor VIIa 61 BAY #-# 61 S/GSK# 61 generation purine nucleoside 61 ESBA# 61 inhibit metastasis 61 Phase 1a clinical 60 Fibrin MB 60 lumiliximab 60 anti CD3 antibody 60 edifoligide 60 Zoraxel 60 Urocortin 2 60 CCR2 60 Granulocyte Colony Stimulating Factor 60 TYSABRI natalizumab 60 REG1 60 CINTREDEKIN BESUDOTOX 60 Catena ® 60 CINQUIL 60 Golimumab 60 Solorel TM 60 Cleviprex TM clevidipine 60 NGX# 60 nucleotide analog 60 cardioprotection 60 Homspera 60 ATL/TV# 60 Seliciclib 60 HER2 overexpression 60 BrachySil ™ 60 Curaxin CBLC# 60 GAMMAGARD 60 pharmacodynamic effects 60 ANG# 60 Preclinical studies 60 trial evaluating PRX# 60 PrevOnco 60 Octreolin 60 TG# [003] 60 osteogenic 60 oral picoplatin 60 Spiegelmer ® 60 CRMD# 60 Pyridorin 60 LymphoStat B TM 60 optimal dosing regimens 60 confirmatory clinical 60 Resten NG 60 Safinamide 60 GLP toxicology studies 60 refractory gout 60 small molecule tyrosine 60 remyelination 60 Fibrillex TM 60 Genz # 60 bosutinib 60 Vitaxin 60 Proxinium TM 60 IRX 2 60 SomatoKine 60 nalbuphine ER 60 kidney urologic 60 pediatric malignancies 60 pharmacodynamic PD 60 targeted radiotherapeutic 60 inhaled iloprost 60 proteasome inhibitor 60 MYDICAR ® 60 obatoclax 60 tecarfarin 60 MAP# 60 dopaminergic therapy 60 visilizumab 60 aerosolized KL4 surfactant 60 Nektar proprietary 60 Anavex #-# 60 PDE4 inhibitor 60 Bicifadine 60 depsipeptide 60 Onrigin 60 KNS # 60 JAK inhibitor 60 Fx #A 60 Zemiva TM 60 p# activation 60 TTF Therapy 60 Allovectin 7 ® 60 neovascular 60 solithromycin 60 Bendavia 60 KIACTA ™ 60 Nicole Onetto MD 60 Kinoid 60 neurotrophic 60 radiation sensitizer 60 trastuzumab DM1 T DM1 60 therapeutic monoclonal antibody 60 ATL# [001] 60 HGS# 60 TRO# 60 cMET 60 oral bioavailability 60 anti CD3 60 STRIDE PD 60 SGS# 60 Anticalins ® 60 Pharmacokinetic studies 60 antiviral potency 60 somatostatin analogue 60 rEV# 60 mTOR inhibition 60 ISIS # 60 EP #R 60 TRV# [001] 60 axitinib 60 Phase IIb clinical trials 60 Acute Radiation Syndrome ARS 60 mertansine 60 Virulizin ® 60 Anticalin ® 60 Helicobacter infection 60 AEG# 60 Neo Kidney Augment 60 initiate Phase 1b 60 Vilazodone 60 trastuzumab Herceptin ® 60 TNFa 60 Tasigna prolongs 60 TLK# 60 Onconase 60 mGluR2 NAM 60 Abbokinase 60 endotoxemia 60 pharmacological chaperone 60 Oral NKTR 60 sargramostim 60 intranasal delivery 60 Inosine 60 vascular disrupting 60 demonstrated antitumor activity 60 hoFH 60 glufosfamide 60 GLYX 60 MyVax ® 60 evaluating tivozanib 60 oritavancin 60 Pimavanserin 60 selective inhibition 60 pharmacodynamic markers 60 Combidex 60 ONCONASE R 60 ACZ# 60 alagebrium 60 phosphatidylserine PS targeting 60 bafetinib 60 vascular insufficiency 60 Archexin 60 ponatinib 59 choroidal vasculopathy 59 gefitinib Iressa 59 ON #.Na 59 basal bolus regimen 59 EOquin TM 59 MEK inhibitor RDEA# 59 Zenvia ™ 59 anti amnesic 59 PNH patients 59 neuroprotectant 59 inecalcitol 59 RhuDex ® 59 peritumoral brain edema 59 Plicera 59 oral FTY# 59 imatinib resistance 59 renoprotective 59 HepDirect technology 59 CDK inhibitors 59 Lpathomab 59 MMP inhibitors 59 ocular formulation 59 TH# [003] 59 Phase #/#a trial 59 cilengitide 59 Chrysalin 59 Azixa 59 pharmacokinetic equivalence 59 EFAPROXYN 59 histamine dihydrochloride 59 angiographic outcomes 59 cediranib 59 YONDELIS 59 antitumor effects 59 Posiphen 59 fulvestrant 59 ZYBRESTAT 59 PROactive study 59 immune modulating 59 AMPK activators 59 Angiolix 59 cerebral ischemia 59 Inhaled nitric oxide 59 INTEGRILIN 59 sitaxsentan 59 Cloretazine R 59 SERCA2a 59 alemtuzumab MS 59 investigational monoclonal antibody 59 VitiGam 59 Ramoplanin 59 teratogenicity 59 somatostatin analogues 59 oncomodulin 59 anti EGFR antibody 59 davunetide intranasal AL 59 CEQ# 59 Phase 2a trial 59 ASONEP 59 bardoxolone 59 HGS ETR1 59 Technosphere Insulin 59 anticancer therapy 59 genotypic resistance 59 TKM ApoB 59 reslizumab 59 VA# [002] 59 bronchodilatory 59 paricalcitol 59 clevidipine 59 OMS# 59 Aflibercept 59 samalizumab 59 GALNS 59 OncoVex 59 Atrasentan 59 motesanib 59 ospemifene 59 retinal vein occlusion induced 59 alpha antagonist 59 Exelixis compounds 59 teduglutide 59 FBPase 59 crizotinib PF # 59 JAK3 59 lesinurad 59 taxane resistant 59 chemotherapy induced neutropenia 59 Sphingomab 59 neratinib 59 Traficet EN 59 aldehyde dehydrogenase ALDH2 deficiency 59 neuronal differentiation 59 GGF2 59 HQK 59 elotuzumab 59 heterozygous FH 59 Relivar 59 OvaRex R 59 targeting PCSK9 59 Corlux 59 volociximab 59 SYN# 59 BCR ABL inhibitors 59 tolevamer 59 AZILECT R 59 COMT inhibitors 59 choroidal neovascularization 59 Curaxin 59 virus HCV protease inhibitor 59 molecular chaperone 59 antisense inhibitors 59 Tarceva TM 59 OMNARIS HFA 59 Preclinical studies suggest 59 arimoclomol 59 immune modulation 59 ICA # 59 Soliris eculizumab 59 plasma kallikrein inhibitor 59 CXB# 59 CaPre TM 59 multicenter trials 59 aerosolized AAT 59 PSN# [001] 59 TB4 59 anti angiogenic drugs 59 rxRNA 59 lucinactant 59 Pagoclone 59 RSD# oral 59 cobiprostone 59 Amplimexon 59 Hepatocellular Carcinoma HCC 59 vemurafenib 59 bucindolol 59 methylation markers 59 severe hypercholesterolemia 59 Dacogen injection 59 Cerashield 59 ELND# 59 mechanistic insights 59 lenalidomide dexamethasone 59 NP2 Enkephalin 59 XL# XL# 59 RLY# 59 corticosteroid dexamethasone 59 tramiprosate 59 CG# [003] 59 atherosclerosis regression 59 Retisert 59 rFVIIa 59 PlGF 59 mapatumumab 59 class mGluR5 inhibitor 59 SILENOR 59 fibrin deposition 59 surrogate endpoint 59 antiangiogenic agents 59 Zevalin consolidation 59 pro angiogenic 59 Onalta ™ 59 edifoligide E2F Decoy 59 phase IIb trial 59 INTERCEPT red 59 immunomodulatory therapy 59 inhibiting telomerase 59 CDK inhibitor 59 Trofex TM 59 xenograft 59 Aclidinium 59 Capesaris 59 PI3 kinase inhibitors 59 erythropoietic 59 next generation URAT1 59 NexACT 59 Insegia 59 pomalidomide 59 Anticalins R 59 immunological responses 59 Eg5 59 pradefovir 59 chemoradiotherapy 59 safinamide 59 rHuPH# 59 TOCOSOL Camptothecin 59 APTIVUS r 59 DCCR 59 ischemia induced 59 DASISION 59 Homspera ® 59 SGLT2 inhibitors 59 orally bioavailable 59 GFT# 59 ataluren 59 immunological diseases 59 Azedra TM 59 Androxal TM 59 tumor necrosis 59 CCR9 59 XP# XP# 59 Desmoteplase 59 NTx TM -# 59 canakinumab 59 Factor Xa inhibitor 59 #mg dose [002] 59 talabostat 59 ongoing Phase 1b 58 metastatic neuroendocrine tumors 58 Degarelix 58 Ketotransdel 58 GAP #B# 58 genetic biomarkers 58 Cerovive 58 histone deacetylase HDAC inhibitor 58 factor Xa inhibitor 58 pain palliation 58 TNF alpha inhibitor 58 HGS ETR1 mapatumumab 58 IAP inhibitor 58 interferon gamma 1b 58 JAK inhibitors 58 KRN# 58 PDE7 inhibitors 58 Tyrima 58 VELCADE melphalan 58 angiogenesis inhibitor 58 IOP lowering 58 thalidomide Thalomid 58 inhibiting mTOR 58 rhIGFBP 3 58 docetaxel Taxotere ® 58 Vascugel ® 58 Azedra ™ 58 opioid antagonists 58 TBC# 58 ALK inhibitor 58 potent inhibition 58 PAOD 58 HDAC inhibition 58 Phenserine 58 noninfectious uveitis 58 systemic immunosuppressive drugs 58 AZILECT ® 58 TOLAMBA 58 beta Estradiol 58 Imprime PGG 58 IMA# 58 oxypurinol 58 Phase Ib clinical 58 Solazed 58 ATL# [002] 58 TNF alpha antagonist 58 Aliskiren 58 tanespimycin 58 MOZOBIL 58 MEK inhibitors 58 zalutumumab 58 EGS# 58 calcitonin 58 PROSTVAC TM 58 prostanoid 58 potent antiproliferative 58 pharmacokinetic interactions 58 Specifid 58 HGS ETR2 58 ganaxolone 58 prospective multicenter study 58 teriflunomide 58 gemifloxacin 58 PEGylated anti 58 busulfan 58 pharmacodynamic profiles 58 oral JAK1 58 complete cytogenetic response 58 THR beta agonist 58 SinuNase 58 Tarvacin TM 58 receptor inhibitor 58 Aurora kinase inhibitor 58 histone deacetylase HDAC 58 OXIGON TM 58 syngeneic 58 pharmacokinetic PK 58 AEOL # 58 HuCNS SC cells 58 PROMACTA 58 cardiac repolarization 58 salmeterol fluticasone 58 tizanidine hydrochloride short 58 Vascugel 58 bortezomib Velcade 58 Xelox 58 BRAF inhibitors 58 PDE4 inhibitors 58 efaproxiral 58 SPC# [001] 58 CYP #A# 58 rhThrombin 58 neurologic progression 58 PDGF receptor 58 cardiac valvulopathy 58 antiarrhythmic 58 pharmacokinetic properties 58 biodistribution studies 58 oral salmon calcitonin 58 percutaneous biopsy 58 imetelstat 58 cangrelor 58 paliperidone ER 58 oral methylnaltrexone 58 Protexia R 58 maximally tolerated dose 58 prion infection 58 liposomal formulation 58 varespladib 58 myeloproliferative 58 hGH CTP 58 radiolabeled TM# 58 OPAXIO 58 plasma pharmacokinetics 58 CIMZIA TM certolizumab pegol 58 renal toxicity 58 Revimmune 58 NOD mouse 58 LB# [003] 58 Optiquel ™ 58 TriRima 58 T#I [002] 58 G#DT 58 KSP inhibitors 58 Prosaptide 58 GLPG# 58 tremelimumab 58 anidulafungin 58 Achieves Primary Endpoint 58 Rasilez Tekturna 58 deforolimus 58 CR# vcMMAE 58 ISTODAX 58 Poly ICLC 58 thromboxane A2 58 symptomatic paroxysmal AF 58 LUVENIQ 58 clonogenic 58 IND submission 58 naronapride 58 Hedgehog inhibitor 58 haematologic 58 Tavocept 58 Asentar 58 retapamulin 58 pDCs 58 cardioprotective effects 58 systemic RNAi 58 ibudilast 58 cisplatin resistant 58 arterial thrombosis 58 amrubicin 58 HCV NS5B polymerase 58 alpha#beta# integrin 58 menadione 58 novel peptide 58 tranilast 58 pharmacokinetic PK profile 58 phase IIb study 58 adrenal suppression 58 sorafenib Nexavar 58 TASKi3 58 gastrin 58 incyclinide 58 insulin sensitizing 58 Pseudomonas aeruginosa infections 58 AEGR 58 acetonide FA 58 Amrubicin 58 ONTAK 58 Bezielle 58 neurosensory 58 investigational humanized monoclonal antibody 58 RSD# 58 Cethromycin 58 pharmacokinetic characteristics 58 HER2 expression 58 SLx 58 goserelin 58 nanoviricide 58 antiplatelet therapies 58 Nasulin 58 faropenem 58 Lisofylline LSF 58 siRNA knockdown 58 SIRT1 activators 58 virological response 58 HDL Selective Delipidation 58 JAK2 inhibitor 58 generation antisense inhibitor 58 O PPDS 58 Alvesco R 58 BRIM2 58 SonoLysis 58 Cannabinor 58 MyVax personalized immunotherapy 58 Cimzia TM 58 ischemic tissues 58 cleavable linker 58 hepatic toxicity 58 rifalazil 58 Virulizin R 58 potently inhibited 58 ZYBRESTAT fosbretabulin 58 successfully commercialize Iluvien 58 Silodosin 58 ADAMTS# 58 Tamibarotene 58 torsemide ER 58 neovascularisation 58 PEGylated interferon 58 topical formulations 58 VP# [004] 58 Synavive 58 orally dosed 58 PET tracers 58 LT NS# 58 verteporfin 58 intracoronary 58 APTIMA HPV 58 TLR antagonists 58 inhibit KSP 58 CORT # 58 QTinno 58 Anticalin R 58 erlotinib Tarceva 58 chemotherapeutic drug 58 DFMO 58 SERMs 58 favorable pharmacokinetic 58 CRD5 58 Enzastaurin 58 HepDirect prodrug 58 Aurora kinase 58 Tolvaptan 58 GTC recombinant human 58 neuropilin 58 cardiac toxicity 58 fusion enhancers 58 CRLX# 58 HyQ 58 adalimumab Humira 58 dose proportionality 58 MAXY VII 58 NAGS deficiency 58 Sudhir Agrawal D.Phil 58 pemetrexed Alimta 58 neuroinflammatory 58 Nuvion 58 lung fibrosis 58 choroidal neovascularization CNV 58 antiresorptive 58 DU #b 58 cartilage regeneration 58 DP b# 58 potent topoisomerase II 58 pegaptanib 58 indibulin 58 AVN# [001] 57 trastuzumab DM1 57 IGF 1R inhibitor 57 TriGrid ™ 57 brostallicin 57 posaconazole 57 aurora kinase 57 INTERCEPT platelets 57 diabetic neuropathic pain 57 stratifying patients 57 NF kappaB activation 57 colorectal cancer liver metastases 57 squalamine 57 HoFH 57 PrevOnco ™ 57 DGAT1 inhibitors 57 prostate carcinogenesis 57 ALN HPN 57 NEVO ™ 57 therapeutic modality 57 IL# PE 57 Phase #b/#a trial 57 Ophena TM 57 Viprinex TM 57 miRview ™ squamous 57 p# inhibitor 57 antibody MAb 57 microplasmin 57 darapladib 57 Nanobodies ® 57 mineralocorticoid receptor 57 TYZEKA 57 MAXY G# 57 PNP inhibitor 57 thrombolytic agents 57 huN# DM1 57 potent suppressor 57 Byetta LAR 57 Kevetrin 57 inhaled nitric oxide 57 XL# SAR# 57 TPI ASM8 57 intradermal injection 57 GEM OS1 57 PRIMO CABG 57 FVIIa 57 endothelin antagonists 57 antidiabetic drugs 57 PCA3 assay 57 antithrombotic agents 57 anticancer compound 57 inhibit EGFR 57 lenalidomide Revlimid R 57 intravesical 57 molecular biomarkers 57 malignant transformation 57 treating neuropathic pain 57 antihypertensive therapies 57 malignant ascites 57 pexiganan 57 adrenergic regulation 57 ancrod 57 chemoresistant 57 cathepsin K 57 SURFAXIN r 57 eniluracil 57 Adentri 57 SPIRIVA HandiHaler 57 systemic fungal infections 57 eculizumab 57 BACcel 57 Lung transplantation 57 deferiprone 57 biologic DMARD 57 osteoinductive 57 diagnostic biomarker 57 PTHrP 57 r hGH 57 dirucotide 57 TELCYTA 57 anti androgens 57 PRTX 57 Removab 57 flavopiridol 57 Cytolin R 57 Squalamine 57 Enzyme Replacement Therapy 57 Exherin TM 57 Plasmin 57 Diamyd r vaccine 57 KRAS status 57 HspE7 57 Ampakine 57 Leber Hereditary Optic Neuropathy 57 otelixizumab 57 DOS# 57 HIF 1a 57 Zemplar Capsules 57 insulin analogs 57 AzaSite Plus 57 heavily pretreated 57 Interferon alpha 57 synthetic retinoid 57 humoral antibody 57 GED aPC 57 xenograft models 57 ThGRF 57 vitro studies 57 radezolid 57 HCV protease inhibitor 57 epigenetic therapies 57 atrial tachyarrhythmias 57 Amigal 57 carcinogenicity study 57 ALN PCS 57 Fc fusion protein 57 INS# [001] 57 cytoprotective 57 antiandrogens 57 orally administered inhibitor 57 erlotinib Tarceva ® 57 CoFactor 57 dose proportional pharmacokinetics 57 oxysterols 57 dose cohort 57 vivo 57 renin inhibitors 57 prognostic biomarker 57 Notch1 57 octreotide 57 intravascular hemolysis 57 protein tyrosine phosphatase 1B 57 TKM Ebola 57 nanopharmaceutical 57 Phenoptin 57 Aggrastat ® tirofiban hydrochloride 57 triglyceride lowering 57 LSI #P 57 senicapoc 57 Vidaza azacitidine 57 skeletal metastases 57 ALB # 57 vorinostat 57 ExTRACT TIMI 57 PhG alpha 1 57 p# biomarker 57 Smac mimetic 57 OGG1 57 Thiovir 57 Solulin 57 drug GAP #B# 57 refractory acute myeloid 57 castrate resistant prostate cancer 57 oral talactoferrin 57 therapeutic regimens 57 experimental autoimmune encephalomyelitis 57 5 HT2C receptor 57 TOCOSOL Paclitaxel 57 PRX # 57 H#N# VLP vaccine 57 biomarker assay 57 Prodarsan R 57 hepatic fibrosis 57 CXCR7 57 RNA antagonist 57 AA Amyloidosis